Indian consensus on the managemeNt of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II).

IF 4.2 2区 医学 Q1 INFECTIOUS DISEASES
Rajeev Soman, Balaji Veeraraghavan, Ashit Hegde, Subhash Varma, Subhash Todi, R K Singh, Vasant Nagavekar, Camilla Rodrigues, Subramanian Swaminathan, V Ramsubramanian, Abdul Ansari, Dhruva Chaudhry, Amullya Pednekar, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate
{"title":"Indian consensus on the managemeNt of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II).","authors":"Rajeev Soman, Balaji Veeraraghavan, Ashit Hegde, Subhash Varma, Subhash Todi, R K Singh, Vasant Nagavekar, Camilla Rodrigues, Subramanian Swaminathan, V Ramsubramanian, Abdul Ansari, Dhruva Chaudhry, Amullya Pednekar, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate","doi":"10.1080/14787210.2024.2360116","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The rising challenge of carbapenem-resistant Enterobacterales (CRE) infections in Indian healthcare settings calls for clear clinical guidance on the management of these infections. The Indian consensus on the management of CRE infection in critically ill patients (ICONIC-II) is a follow-up of the ICONIC-I study, which was undertaken in 2019.</p><p><strong>Areas covered: </strong>A modified Delphi method was used to build expert consensus on CRE management in India, involving online surveys, face-to - face expert meetings, and a literature review. A panel of 12 experts was formed to develop potential clinical consensus statements (CCSs), which were rated through two survey rounds. The CCSs were finalized in a final face-to - face discussion. The finalized CCSs were categorized as consensus, near consensus, and no consensus.</p><p><strong>Expert opinion: </strong>The outcomes included 46 CCSs (consensus: 40; near consensus: 3; and no consensus: 3). The expert panel discussed and achieved consensus on various strategies for managing CRE infections, emphasizing the significance of existing and emerging resistance mechanisms, prompt and tailored empiric therapy, and use of combination therapies. The consensus statements based on the collective expertise of the panel can potentially assist clinicians in the management of CRE infections that lack high-level evidence.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"453-468"},"PeriodicalIF":4.2000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2360116","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The rising challenge of carbapenem-resistant Enterobacterales (CRE) infections in Indian healthcare settings calls for clear clinical guidance on the management of these infections. The Indian consensus on the management of CRE infection in critically ill patients (ICONIC-II) is a follow-up of the ICONIC-I study, which was undertaken in 2019.

Areas covered: A modified Delphi method was used to build expert consensus on CRE management in India, involving online surveys, face-to - face expert meetings, and a literature review. A panel of 12 experts was formed to develop potential clinical consensus statements (CCSs), which were rated through two survey rounds. The CCSs were finalized in a final face-to - face discussion. The finalized CCSs were categorized as consensus, near consensus, and no consensus.

Expert opinion: The outcomes included 46 CCSs (consensus: 40; near consensus: 3; and no consensus: 3). The expert panel discussed and achieved consensus on various strategies for managing CRE infections, emphasizing the significance of existing and emerging resistance mechanisms, prompt and tailored empiric therapy, and use of combination therapies. The consensus statements based on the collective expertise of the panel can potentially assist clinicians in the management of CRE infections that lack high-level evidence.

印度重症患者耐碳青霉烯类肠杆菌感染管理共识 II(ICONIC II)。
导言:印度医疗机构中耐碳青霉烯类肠杆菌(CRE)感染的挑战日益严峻,这就要求对此类感染的管理提供明确的临床指导。印度重症患者 CRE 感染管理共识(ICONIC-II)是 2019 年开展的 ICONIC-I 研究的后续研究:采用改良德尔菲法就印度的 CRE 管理达成专家共识,包括在线调查、面对面专家会议和文献综述。由 12 位专家组成的小组制定了潜在的临床共识声明 (CCS),并通过两轮调查对这些声明进行了评级。在最后的面对面讨论中,最终确定了临床共识声明。最终确定的 CCS 被分为共识、接近共识和无共识:结果包括 46 份综合传播战略(共识:40 份;接近共识:3 份;无共识:3 份)。专家小组就处理 CRE 感染的各种策略进行了讨论并达成了共识,强调了现有和新出现的耐药机制、及时和有针对性的经验疗法以及使用联合疗法的重要性。基于专家组集体专业知识的共识声明有可能帮助临床医生处理缺乏高级别证据的 CRE 感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信